Small molecule · developed by RedHill Biopharma
Upamostat (WX-671) is an orally administered capsule formulation of 200 mg per capsule. It is studied in COVID-19.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04723537 | Phase 2/3 | Covid19 | Terminated | RDHL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Covid19
Updated Oct 25, 2026. Something wrong or missing? Report it on the RDHL page.
See RDHL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RDHL catalysts and pipeline →